Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medplus Health Services Limited has informed exchanges that its subsidiary Optival Health Solutions Private Limited received a suspension order for the Drug License of one store located at Nanded road, Naigaon, Amravati, Maharashtra. The order was issued by the Assistant Commissioner & Licensing Authority, Food & Drug Administrations, Amravati, on August 22, 2025, under Rule 65 of the Drugs and Cosmetics Act, 1940. The suspension is for a period of 30 days. The company has stated the potential revenue loss from this suspension is approximately Rs 6.45 lakhs.
The impact is minimal, limited to a potential revenue loss of around Rs 6.45 lakhs from a single store's 30-day license suspension. This is a routine regulatory action and unlikely to materially affect the company's overall operations or stock price.